Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$6.98 USD
-0.04 (-0.57%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $6.99 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Astria Therapeutics, Inc. has a market cap of $396.17M, which represents its share price of $7.02 multiplied by its outstanding shares number of 56.43M. As a small-cap company, ATXS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ATXS 6.98 -0.04(-0.57%)
Will ATXS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATXS
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?
ATXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ATXS
Astria Therapeutics licenses navenibart rights in Japan to Kaken Pharmaceutical
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and ...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS ...
Astria: Betting On Navenibart In The Crowded HAE Arena
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National ...